Alnylam Pharmaceuticals ALNY GIVLAARI — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Alnylam Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Alnylam Pharmaceuticals’s 10-Q, filed July 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Alnylam Pharmaceuticals's givlaari — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Alnylam Pharmaceuticals's GIVLAARI — total revenues?
- Alnylam Pharmaceuticals (ALNY) reported GIVLAARI — total revenues of $89.76M in Q2 2026.
- How has Alnylam Pharmaceuticals's GIVLAARI — total revenues changed year-over-year?
- Alnylam Pharmaceuticals's GIVLAARI — total revenues increased by 11.0% year-over-year, from $80.85M to $89.76M.
- What is the long-term trend for Alnylam Pharmaceuticals's GIVLAARI — total revenues?
- Over 4 years (2021 to 2025), Alnylam Pharmaceuticals's GIVLAARI — total revenues has grown at a 24.6% compound annual growth rate (CAGR), from $127.82M to $308.49M.
- What does GIVLAARI — total revenues mean?
- This metric represents the total gross revenue generated from the commercial sale of a specific therapeutic product within the company's portfolio. It reflects the market adoption, pricing strategy, and patient demand for this particular treatment in its indicated therapeutic area. Monitoring this figure helps investors assess the product's lifecycle stage and its contribution to the company's overall top-line growth.